193 related articles for article (PubMed ID: 32797086)
1. Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation.
Grosset AA; Dallaire F; Nguyen T; Birlea M; Wong J; Daoust F; Roy N; Kougioumoutzakis A; Azzi F; Aubertin K; Kadoury S; Latour M; Albadine R; Prendeville S; Boutros P; Fraser M; Bristow RG; van der Kwast T; Orain M; Brisson H; Benzerdjeb N; Hovington H; Bergeron A; Fradet Y; Têtu B; Saad F; Leblond F; Trudel D
PLoS Med; 2020 Aug; 17(8):e1003281. PubMed ID: 32797086
[TBL] [Abstract][Full Text] [Related]
2. Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens.
Plante A; Dallaire F; Grosset AA; Nguyen T; Birlea M; Wong J; Daoust F; Roy N; Kougioumoutzakis A; Azzi F; Aubertin K; Kadoury S; Latour M; Albadine R; Prendeville S; Boutros P; Fraser M; Bristow RG; van der Kwast T; Orain M; Brisson H; Benzerdjeb N; Hovington H; Bergeron A; Fradet Y; Têtu B; Saad F; Trudel D; Leblond F
J Biomed Opt; 2021 Nov; 26(11):. PubMed ID: 34743445
[TBL] [Abstract][Full Text] [Related]
3. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
4. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.
Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
Hum Pathol; 2014 Aug; 45(8):1572-81. PubMed ID: 24842280
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
[TBL] [Abstract][Full Text] [Related]
7. Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.
Iczkowski KA; Egevad L; Ma J; Harding-Jackson N; Algaba F; Billis A; Camparo P; Cheng L; Clouston D; Comperat EM; Datta MW; Evans AG; Griffiths DF; Guo CC; Hailemariam S; Huang W; Humphrey PA; Jiang Z; Kahane H; Kristiansen G; La Rosa FG; Lopez-Beltran A; MacLennan GT; Magi-Galluzzi C; Merrimen J; Montironi R; Osunkoya AO; Picken MM; Rao N; Shah RB; Shanks JH; Shen SS; Tawfik OW; True LD; Van der Kwast T; Varma M; Wheeler TM; Zynger DL; Sahr N; Bostwick DG
Ann Diagn Pathol; 2014 Dec; 18(6):333-42. PubMed ID: 25263387
[TBL] [Abstract][Full Text] [Related]
8. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.
Trinh VQ; Benzerdjeb N; Chagnon-Monarque S; Dionne N; Delouya G; Kougioumoutzakis A; Sirois J; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Zorn KC; Fradet Y; Saad F; Taussky D; Trudel D
Radiat Oncol; 2019 Apr; 14(1):60. PubMed ID: 31018850
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
[TBL] [Abstract][Full Text] [Related]
11. [Distribution of intraductal carcinoma of the prostate and associated lesions in the cancer foci on radical prostatectomy specimens].
Sakamoto N; Maki T; Kobayashi S; Kobayashi T; Hamaguchi M; Yoshikawa M; Iguchi A; Momosaki S; Nakayama Y
Nihon Hinyokika Gakkai Zasshi; 2014 Oct; 105(4):163-70; discussion 171. PubMed ID: 25757345
[TBL] [Abstract][Full Text] [Related]
12. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
[TBL] [Abstract][Full Text] [Related]
13. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.
Han B; Suleman K; Wang L; Siddiqui J; Sercia L; Magi-Galluzzi C; Palanisamy N; Chinnaiyan AM; Zhou M; Shah RB
Am J Surg Pathol; 2010 Apr; 34(4):478-85. PubMed ID: 20220513
[TBL] [Abstract][Full Text] [Related]
14. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
[TBL] [Abstract][Full Text] [Related]
15. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival.
Trinh VQ; Sirois J; Benzerdjeb N; Mansoori BK; Grosset AA; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Ladouceur M; Fradet Y; Saad F; Trudel D
Prostate; 2018 Jul; 78(10):697-706. PubMed ID: 29603326
[TBL] [Abstract][Full Text] [Related]
16. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
[TBL] [Abstract][Full Text] [Related]
18. Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.
Dawkins HJ; Sellner LN; Turbett GR; Thompson CA; Redmond SL; McNeal JE; Cohen RJ
Prostate; 2000 Sep; 44(4):265-70. PubMed ID: 10951489
[TBL] [Abstract][Full Text] [Related]
19. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
Guo CC; Epstein JI
Mod Pathol; 2006 Dec; 19(12):1528-35. PubMed ID: 16980940
[TBL] [Abstract][Full Text] [Related]
20. Presence of corpora amylacea among prostate cancer cells: an unrecognised feature of intraductal carcinoma of the prostate.
Sugie M; Takahara T; Ohashi A; Sassa N; Tsuzuki T
Pathology; 2021 Aug; 53(5):574-578. PubMed ID: 34154844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
